Running title: Regorafenib and cetuximab overcome resistance to cetuximab Keywords: Regorafenib, cetuximab, CRC,primary and acquired resistance. Therefore, the blockade of multiple growth factor and receptor pathways could be necessary to increase the efficacy of anti-EGFR monoclonal antibodies. In this study, we have demonstrated that, in human CRC cells with either primary or acquired resistance to cetuximab, the combined treatment with cetuximab and regorafenib induced synergistic anti-proliferative and apoptotic effects and causes significant tumor growth inhibition. This study provides a rationale for evaluating combined treatment with cetuximab and regorafenib as a therapeutic strategy for preventing and/or overcoming cetuximab resistance in mCRC patients. 
Introduction
CRC is one of the leading causes of cancer-related mortality worldwide, with over 1,2 million new cases and 608,700 deaths estimated in 2008 (1) .Despite improvements made in screening strategies, a significant number of patients are still diagnosed at late stages of the disease.
In the last decade, the introduction of targeted therapies in clinical practice, in particular of agents targeting the vascular endothelial growth factor (VEGF)-related pathway (bevacizumab and aflibercept) and the EGFR (cetuximab and panitumumab) has changed the therapeutic approach to metastatic CRC patients, with a significant improvement in progression free survival (PFS) and overall survival (OS) (2) .Cetuximab and panitumumab are monoclonal antibodies (Mabs) that block the activation of the EGFR and of its downstream intracellular signals, the RAS-RAF-MEK-MAPK and the PTEN-PIK3CA-AKT pathways (3) (4) (5) (6) .These two drugs are currently approved for the treatment of metastatic CRCpatients with all-RAS wild-type tumors. Nevertheless, prognosis remains poor for most of these patients. In fact, the use of these monoclonal antibodiesis limited by the presence of pre-existing intrinsic resistance mechanisms or by the ability of cancer cells to acquire resistance. Possible mechanisms for primaryand acquired resistance to cetuximab include mutations in the KRAS, BRAF and NRAS genes,secondary mutation (S492R) in the extracellular domain of EGFR,HER2gene amplification and/or increased HER2 signaling and overexpression of the METpathway (7) (8) (9) (10) .
Recently, it has been elucidated thatin the resistance to anti-EGFR therapiesdifferent growth factors and receptors could be activated in the cancer cell to drive alternative signaling pathways that bypass the EGFR (11, 12) . Molecular heterogeneity also plays an important role in the context of resistance, by limiting the success of therapies against a single target. Colorectal cancer patients can harbor different gene mutations in distinct tumor lesions, or even within different regions of the same lesion (13) .All these alterations could converge on activation of the RAS-MEK-ERK pathway (9, 10, 14, 15) . Understanding the biology of such complex gene heterogeneity in tumors is necessaryfor developing rational combination therapies. In fact, blockade of multiple growth factor and growth factor receptor pathways could be needed to increase the efficacy of anti-EGFR targeted therapies (16) .
Regorafenibis an oral multikinase inhibitor, that could target three key oncogenic pathways, such as a) cell growth by inhibition of KIT, RET, RAF-1 and BRAF; b)tumor-induced angiogenesisby targeting VEGFR1, 2 and-3, and the tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2); and c) tumor microenvironment by blockingplatelet-derived growth factor receptor-β (PDGR-β) and fibroblast growth factor receptor (FGFR) (17) (18) (19) . In preclinical studies, regorafenib exhibited antitumor activity in different tumor xenografts (17) .Recently, a phase III study showed that regorafenib treatment significantly improved OS and PFS in patients with metastatic CRC who failed all available therapies (20) .Thus, both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved regorafenib for the treatment of such metastatic CRC patients.
In the present study, we have evaluated the efficacy of regorafenib in combination with cetuximab to overcoming resistance to anti-EGFR MAbsby using different human CRC cell models. We have selected five CRC cell lines with KRAS mutations (SW480, SW620, HCT116, LOVO, HCT15)one with BRAF mutation (HT29) and two cell lines with acquired resistance to cetuximab, that were originally obtained in our laboratory (10, 14, 21) (Supplementary Table 1 ). We have found that combined treatment with cetuximab and regorafenib induced synergistic antiproliferative and pro-apoptotic effects by blocking MAPK and AKT pathways in these CRC cell lines. Moreover, a similar synergistic antitumor activity has beenconfirmed byin vivosubcutaneous and orthotopic CRC xenograftmodels.
Research. euthanized, the tumors were removed using sterile techniques, divided into 2-3 mm-sized pieces, and harvested in PBS on ice. Mice were treated with antibiotics, ticarcillin (50 mg kg −1 i.v.), two hours before and after tumor implantation.Animals were anesthetized with 2,2,2-tribomoethanol 97% TBE, Avertin (Sigma-Aldrich, St. Louis, MO, USA). TBE solution was prepared fresh daily by mixing 0.625 g of 97% crystalline TBE powder with 25 ml sterile 0.9% saline and then injected intraperitoneally at 0.01 ml/g body mass (250 mg/kg).The abdomen was prepped with betadine solution and the surgical site was isolated in a sterile fashion.A laparotomy of 0.5 cm was conducted; the cecum was exteriorized and isolated using pre-cut, sterile gauze. A warm saline solution was used to keep the cecum wet. Subsequently, the cecum wall waslightly damaged and a single tumor fragment from HCT-116 subcutaneous tumors was sutured to the mesenteric border of the cecum wall using 6.0 nylon surgical sutures. Upon completion, the cecum was placed into the abdominal cavity and the abdominal wound was sutured using a 6.0 Ethicon absorbable stitches.
(Ethicon Inc., Somerville, NJ).Fourteen days after the injection, mice were randomly assigned to four groups (7 mice for each group) to receive one of the following treatments. 
Pro-apoptotic effect of cetuximab in combination with regorafenib in CRC cell lines with primary and acquired resistance to anti-EGFR drugs.
Wemeasured the ability of cetuximab and regorafenib as single agents or in combination, to induce apoptosis in CRC cell lines by the Annexin V-FITC assay (Table 1 and Supplementary Figure 3) .
Compared tosingle agent, the combined treatment induced significantly early and late apoptosis in the whole panel of human CRC cell lines with primary or acquired resistance to cetuximab.
Cetuximabplus regorafenib combination exhibits antitumor activity in subcutaneous CRC xenografts models.
We evaluated the in vivo activity of cetuximab alone or in combination with regorafenib in nude mice subcutaneously injected with cetuximab-resistant HCT15, HCT116, GEO-CR or SW48-CR cell lines. Mice were randomly assigned to receive vehicle, cetuximab, regorafenib or their combination and were treated for three weeks. As shown in Figure 3 , treatment with cetuximab had little or no effect on tumor growth in all tumor xenografts. Similar results were obtained in the groups treated with regorafenib alone. On the contrary, the combined treatment significantly inhibited tumor growth compared both to control group and to single agent treatments in all tumor xenografts ( Figure 3) . Single agent and combination treatment protocols were well tolerated by mice and were not accompanied by any major side effect or treatment-related weight loss. No cellular abnormalities were observed in the examined organs, including heart, lung, liver, kidney and spleen derived from all xenograft mouse models (data not shown).
Cetuximab plus regorafenib combination inhibits tumor growth in an orthotopic human CRC
xenograft.
An orthotopicCRC model with HCT 116 CRC cells was established, as describedin Material and
Methods. Both cetuximab and regorafenib were well tolerated, and no significant loss of animal weight was observed in the group of combined treatment, whereas a significant weight lossoccurred Figure 4) .Of interest combined treatment showed a significant antitumor effectcompared tovehicle, cetuximab or regorafenib single agent groups ( Figure 4 and Table 2 ).Mice treated with vehicle had large tumors in the cecum and peritoneum with 100% incidence of regional (mesenteric) lymph node metastases. Mice receiving cetuximab orregorafenib alone had large tumors with 80% and 70% respectively incidence of lymph node metastases.The combined treatment strongly inhibitedthe tumor growth in the cecum and no peritoneum metastases were observed ( Figure 4 and Table 2 ). The combined treatmentwas also evident ontumor vascularization. In fact, tumors in mice treated with vehicle, cetuximab or regorafenib were large and highly vascularized, whereascetuximab plus regorafenib treated mice developed small tumors without evidence of neovascularization. (Figure 4 and Table 2 ). No liver or lung metastases were detected macroscopically in all groups (data not shown). 
regorafenib antitumor activity could be also due in part by its ability to inhibit RAF serine/threonine kinase (41) (42) (43) .
We have previously shown that a mechanism of acquired resistance to EGFR inhibitors could be the increased secretion of VEGF, suggestinga key role fortumor-induced angiogenesis in the development of anti-EGFR resistance (21) In summary, the present study provides experimental evidence that the combined treatment with anti-EGFR drugs, such as cetuximab, and with a multiple signaling pathway inhibitor, such as regorafenib, could be a potential therapeutic strategy to investigate in a clinical setting for overcoming intrinsic or acquired resistance to EGFR inhibitors in CRC patients.
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